Citation: U. Aden et al., A RANDOMIZED CROSS-OVER STUDY ON VARIOUS HORMONAL PARAMETERS OF 2 TRIPHASIC ORAL-CONTRACEPTIVES, Contraception, 58(2), 1998, pp. 75-81
Citation: I. Wiegratz et al., EFFECT OF 2 ORAL-CONTRACEPTIVES CONTAINING ETHINYL ESTRADIOL AND GESTODENE OR NORGESTIMATE ON DIFFERENT LIPID AND LIPOPROTEIN PARAMETERS, Contraception, 58(2), 1998, pp. 83-91
Authors:
KUHL H
JUNGHOFFMANN C
FITZNER M
MARZ W
GROSS W
Citation: H. Kuhl et al., SHORT-TERM AND LONG-TERM EFFECTS ON LIPID-METABOLISM OF ORAL-CONTRACEPTIVES CONTAINING 30 MU-G ETHINYLESTRADIOL AND 150 MU-G DESOGESTREL OR3-KETO-DESOGESTREL, Hormone research, 44(3), 1995, pp. 121-125
Citation: H. Kuhl et al., PRODRUG VERSUS DRUG EFFECTS OF 150 MU-G DESOGESTREL OR 3-KETO-DESOGESTREL IN COMBINATION WITH 30 MU-G ETHINYLESTRADIOL ON HORMONAL PARAMETERS - RELEVANCE OF THE PEAK SERUM LEVEL OF 3-KETO-DESOGESTREL, Hormone research, 44(3), 1995, pp. 126-132
Citation: I. Wiegratz et al., EFFECT OF 2 ORAL-CONTRACEPTIVES CONTAINING ETHINYLESTRADIOL AND GESTODENE OR NORGESTIMATE UPON ANDROGEN PARAMETERS AND SERUM BINDING-PROTEINS, Contraception, 51(6), 1995, pp. 341-346
Citation: C. Junghoffmann et al., SERUM CONCENTRATIONS OF ETHINYLESTRADIOL, 3-KETO-DESOGESTREL, SHBG, CBG AND GONADOTROPINS DURING TREATMENT WITH A BIPHASIC ORAL-CONTRACEPTIVE CONTAINING DESOGESTREL, Hormone research, 38(3-4), 1992, pp. 184-189